Drug Approval | July 27, 2025
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
The company received one observation in the Form-483
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Revenue increased 11.4 per cent to Rs. 8,545 crore
Subscribe To Our Newsletter & Stay Updated
